Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.59 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.57 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14864525 | 0.92 | PDE5A (0.59) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| SCHEMBL20433795 | 0.89 | ADORA3 (0.51) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| SCHEMBL174909 | 0.89 | PDE5A (0.55) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| SCHEMBL24114778 | 0.89 | PDE5A (0.57) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL19934091 | 0.89 | PDE5A (0.57) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 | |
| SCHEMBL26637716 | 0.89 | PDE5A (0.59) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL7512506 | 0.88 | PDE5A (0.58) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL31120372 | 0.88 | PDE5A (0.49) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15745565 | 0.88 | PDE5A (0.56) | PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL25975252 | 0.87 | PDE5A (0.53) | PDE5AGUCY1A1GUCY1B1ADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | ADVERIO PHARMA GMBH (DE) | 2026-05-26 | — | — | US | disclosed |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | TORRENT PHARMACEUTICALS LTD (IN) | 2026-03-05 | — | — | US | disclosed |
| EP-4396185-B1 | SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEM IND LTD (IL) | 2026-02-18 | — | — | EP | disclosed |
| CN-119954802-A | Process for preparing compounds | 阿德弗里奥药品有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954803-A | Process for preparing compounds | 阿德弗里奥药品有限责任公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115697978-B | Process for preparing methyl {4, 6-diamino-2- [ 5-fluoro-1- (2-fluorobenzyl) -1H-pyrazolo [3,4-b ] pyridin-3-yl ] pyrimidin-5-yl } carbamate | 阿德弗里奥药品有限责任公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240352014-A1 | SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2024-10-24 | — | — | US | disclosed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | disclosed |
| CN-118388478-A | Pyrazole derivative and preparation method and application thereof | 河北科技大学 | 2024-07-26 | — | — | CN | disclosed |
| EP-4396185-A1 | SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-2576547-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-26 | — | — | US | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147809-A1 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
| US-12637456-B2 | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} carbamate | POLL, F9, DNMT3B | PDE5A 445/4885GUCY1A1 952/4885GUCY1B1 635/4885 |
| US-20240352014-A1 | SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF | COMT, CYP2D6, PDE6G | PDE5A 173/4885GUCY1A1 452/4885GUCY1B1 899/4885 |
| US-20260062411-A1 | NOVEL SALT OF SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND ITS USES | PDE3B, PDE5A, PDE2A | PDE5A 2/4885GUCY1A1 9/4885GUCY1B1 26/4885 |
| US-20120022084-A1 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | PDE5A 121/4885GUCY1A1 1337/4885GUCY1B1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.